MedTrace Logo

SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer

NCT02704156 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2022-05-13

Study results available
· View outcomes & findings →

Summary

Hypothesis: Survival benefits could be found in SBRT Plus Pembrolizumab and Trametinib compared with SBRT plus gemcitabine.

Conditions

Interventions

DEVICE

Cyberknife plus Pembrolizumab and Trametinib

Radiation therapy plus drug

DEVICE

Cyberknife plus Gemcitabine

Radiation therapy plus drug

Sponsors & Collaborators

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Huo Jun Zhang, MD., PH.D · Changhai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02704156 on ClinicalTrials.gov